Capital Investment Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $245K | Buy |
4,445
+320
| +8% | +$17.3K | ﹤0.01% | 661 |
|
|
2025
Q4 | $202K | Buy |
+4,125
| New | +$192K | ﹤0.01% | 701 |
|
|
2022
Q1 | – | Sell |
-4,199
| Closed | -$231K | – | 601 |
|
|
2021
Q4 | $231K | Sell |
4,199
-12
| -0.3% | -$624 | 0.01% | 520 |
|
|
2021
Q3 | $201K | Sell |
4,211
-666
| -14% | -$33.5K | 0.01% | 545 |
|
|
2021
Q2 | $243K | Buy |
4,877
+170
| +4% | +$8.17K | 0.01% | 504 |
|
|
2021
Q1 | $210K | Sell |
4,707
-102
| -2% | -$4.63K | 0.01% | 506 |
|
|
2020
Q4 | $221K | Buy |
4,809
+105
| +2% | +$4.82K | 0.01% | 477 |
|
|
2020
Q3 | $221K | Sell |
4,704
-84
| -2% | -$4.21K | 0.01% | 452 |
|
|
2020
Q2 | $244K | Buy |
4,788
+207
| +5% | +$10.6K | 0.01% | 422 |
|
|
2020
Q1 | $217K | Sell |
4,581
-516
| -10% | -$27.5K | 0.01% | 411 |
|
|
2019
Q4 | $299K | Buy |
5,097
+123
| +2% | +$6.84K | 0.01% | 405 |
|
|
2019
Q3 | $265K | Buy |
4,974
+50
| +1% | +$2.57K | 0.01% | 414 |
|
|
2019
Q2 | $246K | Sell |
4,924
-190
| -4% | -$9.53K | 0.01% | 424 |
|
|
2019
Q1 | $267K | Sell |
5,114
-538
| -10% | -$26.9K | 0.02% | 404 |
|
|
2018
Q4 | $270K | Sell |
5,652
-794
| -12% | -$39.1K | 0.02% | 381 |
|
|
2018
Q3 | $324K | Sell |
6,446
-156
| -2% | -$7.93K | 0.02% | 374 |
|
|
2018
Q2 | $333K | Buy |
6,602
+76
| +1% | +$3.83K | 0.02% | 373 |
|
|
2018
Q1 | $319K | Sell |
6,526
-1,392
| -18% | -$64.8K | 0.02% | 380 |
|
|
2017
Q4 | $351K | Sell |
7,918
-540
| -6% | -$24.9K | 0.02% | 355 |
|
|
2017
Q3 | $429K | Sell |
8,458
-599
| -7% | -$30.4K | 0.03% | 304 |
|
|
2017
Q2 | $488K | Sell |
9,057
-116
| -1% | -$6.18K | 0.04% | 281 |
|
|
2017
Q1 | $483K | Sell |
9,173
-470
| -5% | -$23.8K | 0.04% | 291 |
|
|
2016
Q4 | $464K | Sell |
9,643
-955
| -9% | -$47.2K | 0.04% | 283 |
|
|
2016
Q3 | $571K | Sell |
10,598
-605
| -5% | -$33.2K | 0.05% | 250 |
|
|
2016
Q2 | $607K | Sell |
11,203
-320
| -3% | -$16.9K | 0.06% | 236 |
|
|
2016
Q1 | $584K | Sell |
11,523
-663
| -5% | -$33K | 0.06% | 234 |
|
|
2015
Q4 | $615K | Sell |
12,186
-146
| -1% | -$7.44K | 0.06% | 218 |
|
|
2015
Q3 | $593K | Buy |
12,332
+550
| +5% | +$28.6K | 0.07% | 212 |
|
|
2015
Q2 | $613K | Buy |
11,782
+1,680
| +17% | +$94.6K | 0.07% | 217 |
|
|
2015
Q1 | $583K | Buy |
10,102
+1,295
| +15% | +$74.2K | 0.06% | 223 |
|
|
2014
Q4 | $471K | Buy |
8,807
+4,735
| +116% | +$265K | 0.05% | 246 |
|
|
2014
Q3 | $234K | Buy |
+4,072
| New | +$250K | 0.03% | 327 |
|
Other funds holding GSK
JEST
Capital Investment Advisors's GSK Position: Q1 2026 in Review
Capital Investment Advisors increased its GSK (GSK) stake by 7.8% in Q1 2026, buying an estimated $17.3K and bringing the position to 4,445 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #661.
Capital Investment Advisors first reported a position in GSK in Q3 2014 and has held it in 32 quarters since. The position peaked at $615K in Q4 2015. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Capital Investment Advisors held 4,445 shares of GSK worth $245K as of Q1 2026.
- Capital Investment Advisors bought 320 GSK shares in Q1 2026, an estimated $17.3K.
- GSK made up ﹤0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #661 holding.
- Capital Investment Advisors first reported a position in GSK in Q3 2014 and has held it in 32 quarters since.
- Capital Investment Advisors's GSK position peaked at $615K in Q4 2015.
- 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.